1. Home
  2. SGRX vs REVB Comparison

SGRX vs REVB Comparison

Compare SGRX & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGRX

SANGRIX INC. Class A Ordinary Shares

N/A

Current Price

$2.39

Market Cap

1.7M

Sector

N/A

ML Signal

N/A

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

N/A

Current Price

$3.69

Market Cap

1.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SGRX
REVB
Founded
2018
2020
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
1.9M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
SGRX
REVB
Price
$2.39
$3.69
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $76.25
AVG Volume (30 Days)
★ 4.2M
11.8K
Earning Date
12-01-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 72.68
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.44
52 Week High
$3.15
$4.75

Technical Indicators

Market Signals
Indicator
SGRX
REVB
Relative Strength Index (RSI) 73.81 55.78
Support Level $1.46 $0.93
Resistance Level $3.15 $4.06
Average True Range (ATR) 0.20 0.40
MACD 0.27 -0.14
Stochastic Oscillator 74.39 19.70

Price Performance

Historical Comparison
SGRX
REVB

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Share on Social Networks: